Stoke Therapeutics, Inc. announced enrollment of the first patient in an observational study of children and adolescents ages 2 to 18 with Dravet syndrome. BUTTERFLY is a two-year observational study that is designed to evaluate seizure frequency and non-seizure comorbidities associated with the disease, including motor and speech impairment, intellectual and developmental disabilities, behavioral deficits and abnormal sleep patterns. Data from the study will support clinical development plans for the company’s lead therapeutic candidate, STK-001, an investigational new treatment for Dravet syndrome.
August 12, 2021
‘To Reveal or to Conceal’- Disclosure Strategies in Parents of Children With Epilepsy in India
Disclosure practices have improved in parents of children with epilepsy in India and well-being and safety of the child has overridden the fear of stigma and discrimination. This could be the first major step to bring epilepsy out of the shadows at national and global levels.